-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Kinnate Biopharma Inc. annual/quarterly Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q4 2022.
- Kinnate Biopharma Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2022 was -$31.6M, a 20.7% decline year-over-year.
- Kinnate Biopharma Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2022 was -$116M, a 29.5% decline year-over-year.
- Kinnate Biopharma Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$113M, a 3.12% increase from 2022.
- Kinnate Biopharma Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$116M, a 29.5% decline from 2021.
- Kinnate Biopharma Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$89.8M, a 151% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)